{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-304984","form_type":"8-K","ticker":"CPRX","cik":"0001369568","company_name":"CATALYST PHARMACEUTICALS, INC.","filed_at":"2026-07-15T21:36:30+00:00","discovered_at":"2026-07-16T10:05:00.274140+00:00","generated_at":"2026-07-16T10:05:38.415890+00:00","sec_items":["2.01","3.01","3.03","5.01","5.02","5.03","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":1.0,"calibrated_materiality_score":1.0,"confidence":"high","headline":"Catalyst Pharmaceuticals completes merger with Angelini Pharma; shareholders receive $31.50/share","bullets":["Merger closed July 15, 2026; each share converted to $31.50 cash, no interest.","Stock to be delisted from Nasdaq; trading suspended July 16, 2026.","All directors resigned; new directors from Angelini (Sergio Marullo di Condojanni, Massimo Marin, Enrica Dogali) appointed.","Certificate of incorporation and bylaws amended and restated.","Company becomes wholly owned subsidiary of Angelini Pharma S.p.A."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-304984","json":"https://secwatch.observer/filing/0001193125-26-304984.json","markdown":"https://secwatch.observer/filing/0001193125-26-304984.md","text":"https://secwatch.observer/filing/0001193125-26-304984.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1369568/000119312526304984/0001193125-26-304984-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1369568/000119312526304984/d159184d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-16T10:05:38.415890+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3dc868bb35","claim":"David S. Tierney, M.D. resigned as Director at CATALYST PHARMACEUTICALS, INC..","evidence_excerpt":"each of the directors of the Company (Patrick J. McEnany; Richard J. Daly; Daniel J. Curran, M.D.; Donald A. Denkhaus; Molly Harper; Tamar Thompson; and David S. Tierney, M.D.) resigned and ceased to be directors of the board of directors of the Company and members of any committee thereof, as applicable.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1369568/000119312526304984/0001193125-26-304984-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"563dd2ab4c","claim":"Enrica Dogali was appointed as Director at CATALYST PHARMACEUTICALS, INC..","evidence_excerpt":"the directors of Merger Sub immediately prior to the Effective Time (Sergio Marullo di Condojanni; Massimo Marin; Enrica Dogali) became the directors of the Surviving Corporation.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1369568/000119312526304984/0001193125-26-304984-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"770daf9052","claim":"Daniel J. Curran, M.D. resigned as Director at CATALYST PHARMACEUTICALS, INC..","evidence_excerpt":"each of the directors of the Company (Patrick J. McEnany; Richard J. Daly; Daniel J. Curran, M.D.; Donald A. Denkhaus; Molly Harper; Tamar Thompson; and David S. Tierney, M.D.) resigned and ceased to be directors of the board of directors of the Company and members of any committee thereof, as applicable.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1369568/000119312526304984/0001193125-26-304984-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"afa3a8d363","claim":"Massimo Marin was appointed as Director at CATALYST PHARMACEUTICALS, INC..","evidence_excerpt":"the directors of Merger Sub immediately prior to the Effective Time (Sergio Marullo di Condojanni; Massimo Marin; Enrica Dogali) became the directors of the Surviving Corporation.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1369568/000119312526304984/0001193125-26-304984-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"b45674162d","claim":"Molly Harper resigned as Director at CATALYST PHARMACEUTICALS, INC..","evidence_excerpt":"each of the directors of the Company (Patrick J. McEnany; Richard J. Daly; Daniel J. Curran, M.D.; Donald A. Denkhaus; Molly Harper; Tamar Thompson; and David S. Tierney, M.D.) resigned and ceased to be directors of the board of directors of the Company and members of any committee thereof, as applicable.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1369568/000119312526304984/0001193125-26-304984-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"b623411a4f","claim":"Tamar Thompson resigned as Director at CATALYST PHARMACEUTICALS, INC..","evidence_excerpt":"each of the directors of the Company (Patrick J. McEnany; Richard J. Daly; Daniel J. Curran, M.D.; Donald A. Denkhaus; Molly Harper; Tamar Thompson; and David S. Tierney, M.D.) resigned and ceased to be directors of the board of directors of the Company and members of any committee thereof, as applicable.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1369568/000119312526304984/0001193125-26-304984-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"e2330f7485","claim":"Patrick J. McEnany resigned as Director at CATALYST PHARMACEUTICALS, INC..","evidence_excerpt":"each of the directors of the Company (Patrick J. McEnany; Richard J. Daly; Daniel J. Curran, M.D.; Donald A. Denkhaus; Molly Harper; Tamar Thompson; and David S. Tierney, M.D.) resigned and ceased to be directors of the board of directors of the Company and members of any committee thereof, as applicable.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1369568/000119312526304984/0001193125-26-304984-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"e84f9c3585","claim":"Donald A. Denkhaus resigned as Director at CATALYST PHARMACEUTICALS, INC..","evidence_excerpt":"each of the directors of the Company (Patrick J. McEnany; Richard J. Daly; Daniel J. Curran, M.D.; Donald A. Denkhaus; Molly Harper; Tamar Thompson; and David S. Tierney, M.D.) resigned and ceased to be directors of the board of directors of the Company and members of any committee thereof, as applicable.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1369568/000119312526304984/0001193125-26-304984-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"ebe76df1ed","claim":"Sergio Marullo di Condojanni was appointed as Director at CATALYST PHARMACEUTICALS, INC..","evidence_excerpt":"the directors of Merger Sub immediately prior to the Effective Time (Sergio Marullo di Condojanni; Massimo Marin; Enrica Dogali) became the directors of the Surviving Corporation.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1369568/000119312526304984/0001193125-26-304984-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"f7f53b8c27","claim":"Richard J. Daly resigned as Director at CATALYST PHARMACEUTICALS, INC..","evidence_excerpt":"each of the directors of the Company (Patrick J. McEnany; Richard J. Daly; Daniel J. Curran, M.D.; Donald A. Denkhaus; Molly Harper; Tamar Thompson; and David S. Tierney, M.D.) resigned and ceased to be directors of the board of directors of the Company and members of any committee thereof, as applicable.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1369568/000119312526304984/0001193125-26-304984-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}